New German Reimbursement Process Splits Opinion Ahead Of First Assessments
Executive Summary
Several drug firms – including, most vociferously, Eli Lilly & Co. – have already concluded that Germany's tough new reimbursement laws are the root of much evil. But others are taking more of a wait-and-see approach to the new system, which demands that companies provide compelling proof, upfront, of the added benefit of their drugs over existing therapies.
You may also be interested in...
German HTA Blueprint Could Be Imposed On Greece
Germany’s role in preparing a health reform agreement between Greece and the World Health Organization may lead to a G-BA/IQWiG-style HTA process being introduced in the Hellenic Republic.
Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher
Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.
U.S. Provides Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher
Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.